Real world data

Seqster Announces The Operating System for Patient Registries and Clinical Studies on Salesforce AppExchange, the World's Leading Enterprise Cloud Marketplace

Retrieved on: 
Tuesday, April 12, 2022
Cloud, Real, DNA, EVP, Multimedia, Genomics, Hospital, Health information management, CEO, View, Laika (EHR testing framework), Real world data, EHR, Collection, Disease, Pharmacy, List of life sciences, Salesforce, RWD, SAN, AI, Patient, RWE, Pharmaceutical industry, Medical device, Medical imaging

SAN DIEGO, April 12, 2022 /PRNewswire/ -- Seqster PDM, Inc. ("Seqster") the leading patient-centric healthcare technology company, today announced it has launched SeqsterOS, the Operating System for Patient Registries and clinical studies on Salesforce AppExchange, empowering life science enterprises to seamlessly integrate patient-consented Real World Data, including electronic health records (EHR), genomics, and device data, with a patient engagement layer for their clinical studies.

Key Points: 
  • "SeqsterOS app is a welcome addition to AppExchange, as they power digital transformation for clients by empowering both clinical trials and patients on Salesforce HealthCloud," said Woodson Martin, EVP & GM of Salesforce AppExchange.
  • Salesforce AppExchange, the world's leading enterprise cloud marketplace, empowers companies, developers and entrepreneurs to build, market, and grow in entirely new ways.
  • Salesforce, AppExchange, Health Cloud and others are among the trademarks of salesforce.com, inc.
    Seqster is the leading healthcare technology company that breaks down health data silos at scale.
  • Its enterprise operating system aggregates disparate health data sources into a single, 360-degree view of a patient in real-time, solving a multitude of challenges for life sciences, patient engagement and data interoperability.

Curebase Adds Two Clinical Trial Veterans to Kick-off New Advisory Board

Retrieved on: 
Monday, February 14, 2022
Health, DCT, Boston University, Patient, CEO, Lviv, Parexel, Neurodegeneration, University of Utah School of Medicine, Rehabilitation, Informatics, SAN, Cros, Clinical trial, RWD, Technology, Neurology, University, Pediatrics, Therapy, Pfizer, Partnership, Public health, Physician, Research, Public health informatics, Harvard Medical School, Real world data, Pharmaceutical industry, Medicine, Medical device, Science

SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ --Curebase, a company committed to democratizing access to clinical studies, has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.

Key Points: 
  • SAN FRANCISCO, Feb. 14, 2022 /PRNewswire/ --Curebase, a company committed to democratizing access to clinical studies, has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.
  • The new board members will help the company develop technology, data, partnership and growth strategies designed to increase its share of the global decentralized clinical trial (DCT) market.
  • The company's virtual research sites also offer patients a unique opportunity to participate in clinical studies, regardless of their location.
  • I look forward to working with Curebase to expand how they leverage and generate RWD in support of clinical research."

Holmusk Enters into Collaboration with Metrocare Services

Retrieved on: 
Tuesday, February 1, 2022
Real-World Evidence, Patient, Natural language processing, Health, Veteran, RWD, Real world data, Research, RWE, Housing, Partnership, Mental health, Disability in Canada, Natural language, Pharmacy, Education, Medicine, Doctor of Philosophy

Metrocare Services is the largest provider of mental health and developmental disability services in North Texas, serving over 55,000 adults and children every year.

Key Points: 
  • Metrocare Services is the largest provider of mental health and developmental disability services in North Texas, serving over 55,000 adults and children every year.
  • "Metrocare and Holmusk share a vision that to achieve the most effective mental health intervention of our time requires robust analytics that drive outcomes," said Dr. John W. Burruss, Metrocare's Chief Executive Officer.
  • Metrocare is the largest provider of behavioral health services in Dallas County, serving nearly 55,000 adults and children annually.
  • For over 50 years, Metrocare has provided a broad array of services to people with mental health challenges and developmental disabilities from mental health care, substance use services, services for veterans and their loved ones, accessible pharmacies, housing, and supportive social services.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Real, Real world data, Patient, Efficiency, Public health, Czech Republic, Growth, Contract research organization, CRO, Acquisition, Health information management, Health, Solution, EDC, Institute, Biotechnology, Federation, Breathing gas, RWE, Research, Clinical trial, Medical device, Public relations, Pharmaceutical industry, EU, EMMS International

ROCKVILLE, Md., Dec. 21, 2021 /PRNewswire/ -- Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany.  Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies.  It has conducted more than 400 studies across a range of therapeutic areas. 

Key Points: 
  • Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.
  • The acquisition of Institut Dr. Schauerte augments Emmes' global reach by expanding the company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Real, Real world data, Patient, Efficiency, Public health, Czech Republic, Growth, Contract research organization, CRO, Acquisition, Health information management, Health, Solution, EDC, Institute, Biotechnology, Federation, Breathing gas, RWE, Research, Multimedia, Clinical trial, Medical device, Public relations, Pharmaceutical industry, EU, EMMS International

Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.

Key Points: 
  • Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-upstudies.
  • The acquisition of Institut Dr. Schauerte augments Emmes' global reach by expanding the company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • With Institut Dr. Schauerte, Emmes now has more than 1,200 employees.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market

Retrieved on: 
Tuesday, December 21, 2021
Clinical trial, RWE, Health, Institute, Federation, Acquisition, Contract research organization, Public health, Investment, Czech Republic, Biotechnology, Research, Solution, Company, Breathing gas, Real, CRO, Real world data, Growth, IDS, Public relations, Pharmaceutical industry, EU, EMMS International

IDS marks the third acquisition for Emmes in the last year and since Behrman's investment in 2019.

Key Points: 
  • IDS marks the third acquisition for Emmes in the last year and since Behrman's investment in 2019.
  • The acquisition of IDS augments Emmes' global reach by expanding the Company's presence in Germany and adding new long-term strategic relationships with global biopharma companies.
  • Grant Behrman, Managing Partner of Behrman Capital, said, "IDS is a highly complementary and additive business that significantly enhances the Emmes platform.
  • Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of Real World Evidence (RWE) research.

Holmusk Announces Closing of Strategic Investment from Healthcare and Life Science Industry Leaders

Retrieved on: 
Monday, December 6, 2021
Real-World Evidence, Patient, News, Natural language, CEO, RWD, Electronic health record, Industry, Hospital, Northwell Health, Holding, Real world data, Physician, Health, RWE, Natural language processing, Drug development, Growth, Pharmaceutical industry, Management

NEW YORK, Dec. 6, 2021 /PRNewswire/ --Holmusk, a leading global data science and digital health company building the world's largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round.

Key Points: 
  • NEW YORK, Dec. 6, 2021 /PRNewswire/ --Holmusk, a leading global data science and digital health company building the world's largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round.
  • "This strategic round marks an exciting milestone for Holmusk as we continue to reinvent the ways in which we care for patients with behavioral health needs."
  • "Today's news demonstrates industry validation of our Real-World Evidence strategy in behavioral health with the addition of leading pharma and provider players," said Nawal Roy, Holmusk Founder & CEO.
  • Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation.

Holmusk Announces Closing of Strategic Investment from Healthcare and Life Science Industry Leaders

Retrieved on: 
Monday, December 6, 2021
Real-World Evidence, Patient, News, Natural language, CEO, RWD, Electronic health record, Industry, Hospital, Northwell Health, Holding, Real world data, Physician, Health, RWE, Natural language processing, Drug development, Growth, Pharmaceutical industry, Management

NEW YORK, Dec. 6, 2021 /PRNewswire/ --Holmusk, a leading global data science and digital health company building the world's largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round.

Key Points: 
  • NEW YORK, Dec. 6, 2021 /PRNewswire/ --Holmusk, a leading global data science and digital health company building the world's largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round.
  • "This strategic round marks an exciting milestone for Holmusk as we continue to reinvent the ways in which we care for patients with behavioral health needs."
  • "Today's news demonstrates industry validation of our Real-World Evidence strategy in behavioral health with the addition of leading pharma and provider players," said Nawal Roy, Holmusk Founder & CEO.
  • Holmusk is on a mission to reinvent behavioral health and transform lives with Real-World Evidence and digital innovation.

Holmusk and Charité - Universitätsmedizin Berlin Enter a Strategic Collaboration to Drive Precision Psychiatry Using Novel Real-World Data

Retrieved on: 
Tuesday, November 23, 2021
Real-World Evidence, Patient, Natural language, Mental health, Psychiatry, Bed, RWD, Social, Partnership, Diagnosis, American Academy of Child and Adolescent Psychiatry, Real world data, Student, Crowned heads of Europe (phrase), Clinician, COVID-19, Department of Social and Preventive Medicine, University of Malaya, Data science, Nursing, Adolescence, Psychosomatic medicine, Research, The Pew Charitable Trusts, RWE, DZP, GDPR, Natural language processing, Preventive healthcare, Medical school, Neuroscience, German Centre for Integrative Biodiversity Research (iDiv), Department, Education, Dentistry, Pharmaceutical industry

The collaboration sets out to enable precision psychiatry for patients, by capturing and analysing real-world data.

Key Points: 
  • The collaboration sets out to enable precision psychiatry for patients, by capturing and analysing real-world data.
  • The strategic collaboration is focused on building multi-site, standardized real-world data capture infrastructure, including both clinician- and patient-reported assessments and outcomes.
  • Curated and digitized data will allow enhanced and real-time quality assessment and form the basis of measurement-based care in Germany.
  • This forward-thinking initiative is made possible by the partnership between Charit and Holmusk, a world leader in real-world data science in psychiatry.

CreakyJoints Reports that Patients Living with Axial Spondyloarthritis Often Choose Treatment Escalation Due to Inadequate Disease Control

Retrieved on: 
Thursday, November 18, 2021
Research, Hospitals, Other Health, Physical Therapy, Managed Care, Health, General Health, Other Science, Science, Patient, Caregiver, Conditional sentence, Company, MD, Real world data, Doctor of Philosophy, University, Education, Eli Lilly and Company, Pain, Veterans Health Administration, Ankylosing spondylitis, Axial spondyloarthritis, Human voice, SD, Female, Joint, Arthritis, Human, Injury, Social media, Fatigue, Body mass index, University of Utah, Associate, Disease management, Disease, Medical device, Pharmaceutical industry

The primary reasons for declining a change in treatment related to not believing there were more effective treatment options or worries about potential side effects of the new treatment.

Key Points: 
  • The primary reasons for declining a change in treatment related to not believing there were more effective treatment options or worries about potential side effects of the new treatment.
  • The top symptoms driving treatment changes overall were pain in back or buttock, pain in other joints, and fatigue.
  • Regardless of the level of treatment satisfaction, most participants (85.3%, n=113) agreed to the treatment change when one was discussed.
  • CreakyJoints is a digital community for millions of arthritis patients and caregivers worldwide who seek education, support, advocacy, and patient-centered research.